Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 219 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cutaneous Squamous Cell Carcinoma Clear all

Conditions: Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Interventions: Cemiplimab, Everolimus, Sirolimus, Prednisone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Wound Healing After MMS Surgery, BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Melanoma In Situ
Interventions: A microsurfaced ADM (acellular dermal matrix); Device
Lead sponsor: McGuire Institute; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rockwall, Texas

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Non-melanomatous Skin Cancer, Precancerous Condition
Interventions: aminolevulinic acid; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Not listed
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions: Fluzone Trivalent; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Interventions: BCA101, Pembrolizumab; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions: TNO155, TNO155 in combination with EGF816 (nazartinib); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions: RTX-224; Drug
Lead sponsor: Rubius Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 2 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-927, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: SCC - Squamous Cell Carcinoma of Skin
Interventions: Vilobelimab, Vilobelimab + pembrolizumab combination therapy; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: La Jolla, California • Aurora, Colorado • Miami, Florida + 3 more

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions: Audiometric Test, Interview; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions: NT-I7, atezolizumab; Drug
Lead sponsor: NeoImmuneTech; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
Interventions: INCB099280; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions: Topical niacinamide 5% cream, Sunscreen; Drug
Lead sponsor: Marissa Lobl; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: nicotine, Usual Care; Drug · Behavioral
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 19 Years to 120 Years
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1990
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cutaneous Squamous Cell Carcinoma
Interventions: Atezolizumab; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma
Interventions: Microdevice; Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
Interventions: ONCR-177, pembrolizumab; Biological
Lead sponsor: Oncorus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 6 more

Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions: IFx-Hu2.0; Biological
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Brandon, Florida

Conditions: Lymphoma, Non-melanomatous Skin Cancer, Precancerous Condition
Interventions: silicon phthalocyanine 4; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions: Cemiplimab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma
Interventions: sentinel lymph node biopsy (SLNB); Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions: Cemiplimab, Standard of care; Drug · Procedure
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 48
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more

Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions: Short course radiation, Active Surveillance; Radiation · Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Burlington, Vermont

Search by objective public record fields.

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Photodynamic Therapy in Treating Patients With Skin Cancer

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

RTX-224 Monotherapy in Patients With Solid Tumors

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer